Sydney Lupkin

Some just aren't into the idea.

They're like, hey, the injections work for me.

Why would I switch?

But overall, the pill is another option, and that's big, especially when it comes to cost.

And that's on top of already high insurance premiums.

So even if you have insurance coverage, it might be really limited or still require a big out-of-pocket payment.

So we don't officially know what the sticker price for the pills is going to be yet.

Novo Nordisk has not said.

Eli Lilly has not said.

But generally, pills are easier to manufacture.

Therefore, they're cheaper to manufacture, which could result in a downstream lower price.

We also know that there have been deals with the Trump administration announced earlier this year to sell the pills to consumers not using their health insurance for $149 a month.

Now, that is not a sticker price, but it could mean that a lower sticker price is coming.

And that could mean better insurance coverage, more access.

Basically, just more people able to get their hands on these if they need them.

Sydney Lupkin, thank you so much for joining us.

Eli Lilly is the company behind blockbuster obesity drug Zepbound.

Now it's working on a next generation medicine.

Eli Lilly's experimental new drug is called Retatrutide.

It's still being studied and hasn't yet been submitted to the Food and Drug Administration for approval, but new study results show that patients taking the highest dose of the drug lost an average of 72 pounds over 68 weeks, according to the company.